IDE 161
Alternative Names: IDE-161Latest Information Update: 07 Mar 2024
At a glance
- Originator IDEAYA Biosciences
- Class Antineoplastics; Small molecules
- Mechanism of Action Poly ADP ribose glycohydrolase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 20 Feb 2024 IDEAYA Biosciences plans a clinical trial for Solid tumours (combination therapy) (PO) in 2024 (IDEAYA Biosciences pipeline, February 2024)
- 20 Feb 2024 IDEAYA Biosciences plans a phase II trial for Solid tumours (Monotherapy) (PO) in 2024 (IDEAYA Biosciences pipeline, February 2024)
- 20 Feb 2024 IDEAYA Biosciences plans to initiate clinical trials of combination of IDE 161 with other therapeutics for the treatment of Solid tumors